ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NURO NeuroMetrix Inc

3.70
0.00 (0.00%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
NeuroMetrix Inc NASDAQ:NURO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.70 3.62 4.07 0 01:00:00

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

20/07/2023 6:00pm

GlobeNewswire Inc.


NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more NeuroMetrix Charts.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q2 2023 business and financial highlights before the opening of the market on July 27, 2023. The Company will host a conference call at 8:00 a.m., Eastern Time on July 27, 2023.

For participants who wish to access the Q2 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and unique PIN will be provided on screen and via email to join the call. An audio-only webcast of the call, along with the earnings press release and accompanying condensed financial statements, may be accessed in the Investors section of the Company’s website at www.NeuroMetrix.com. Following the conference call, a replay of the call will be available for one year on the Company's Investors section of the website.

About NeuroMetrix

NeuroMetrix is a commercial stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell® is a wearable neuromodulation platform. DPNCheck® is a point-of-care screening test for peripheral neuropathy. For more information, visit www.NeuroMetrix.com.

NeuroMetrix, Inc.Thomas T. HigginsSVP and Chief Financial Officerneurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

1 Year NeuroMetrix Chart

1 Year NeuroMetrix Chart

1 Month NeuroMetrix Chart

1 Month NeuroMetrix Chart

Your Recent History

Delayed Upgrade Clock